This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutIndicationsBroad CoverageEfficacyEfficacyLimited Treatment OptionsSafetySafety

Safety Profile Summary 

DosingAdult DosingPaediatric Dosing

Prescribing Information

Adult Dosing

Consistent dosing across indications1

Zavicefta is administered by intravenous infusion over 120 minutes in an appropriate infusion volume (see section 6.6 of SmPC).

Recommended dose for adult patients with estimated CrCl >50 mL/min*

Scroll left to view table

* CrCL estimated using the Cockcroft-Gault formula.
# To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be 
contributing to the infectious process.
To be used in combination with an antibacterial agent active against Gram-positive pathogens when 
these are known or suspected to be contributing to the infectious process.
§ The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy.
** There is very limited experience with the use of Zavicefta for more than 14 days.

Recommended dose for adults with estimated CrCL* ≤ 50 mL/min

* CrCL estimated using the Cockcroft-Gault formula.
# Dose recommendations are based on pharmacokinetic modelling (see section 5.2 of SmPC).
Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2 of SmPC). Dosing of 
Zavicefta on haemodialysis days should occur after completion of haemodialysis.
§ Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are 
based on the ceftazidime component only (see section 6.6 of SmPC)

No dose adjustment required in the elderly patients and those with hepatic impairment.1

Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion
)

Abbreviations:cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; SmPC, Summary of Product Characteristics; VAP, ventilator-associated pneumonia.References:

ZAVICEFTA. Summary of Product Characteristics.

Dosing

Legal Category: S1A

Further information available upon request

PP-ZVA-IRL-0287. December 2024

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0891. February 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0891. February 2025

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0891. February 2025